• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pfizer appeals $107m fine for anti-epilepsy drug prices in UK

February 15, 2017 By Sarah Faulkner

PfizerPfizer appeals $107m fine for anti-epilepsy drug prices in UK (NYSE:PFE) and Flynn Pharma have appealed the record $107 million (£84.2 million) and $6.5 million (£5.2 million) fines imposed by the U.K. Competition & Markets Authority in December for the companies’ massive price hikes to their unbranded versions of anti-epilepsy drug Epanutin.

In its appeal, Pfizer claims that the regulator did not consider market realities when it fined the drugmaker, saying “Pfizer challenges the CMA’s conclusion that it was dominant within the relevant market: the market for the manufacture of Pfizer-manufactured phenytoin sodium capsules that are distributed in the UK. The unrealistically narrow market identified by the CMA flies in the face of the contemporaneous evidence. Furthermore, the CMA’s conclusions on dominance fail to take into account the very substantial countervailing buyer power of the Department of Health.”

New York City-based Pfizer used to market the phenytoin sodium anti-epilepsy treatment as the branded drug Epanutin. The company sold the rights to Flynn in September 2012 and Flynn debranded the drug, removing it from the scrutiny of price regulation, and hiked the price of the capsules by 2,600% to a peak of £67.50 – about $85.16 in today’s dollars – before dropping to £54.00 ($68.11 today).

“The companies deliberately exploited the opportunity offered by debranding to hike up the price for a drug which is relied upon by many thousands of patients,” CMA’s case decision group chairman Philip Marsden said when the group made its original decision, according to Reuters.

The CMA explained that British prices for the drug were higher than anywhere else in Europe and that Britain’s National Health service spent £50 million ($58.3 million) in 2013 for the capsules, a 2,400% jump from the year before.

“Phenytoin capsules were a loss-making product for Pfizer and the Flynn transaction represented an opportunity to secure ongoing supply of an important medicine for patients with epilepsy, while maintaining continuity of manufacture,” Pfizer said in a statement. “When Flynn launched its product, the company set a price that was between 25 and 40% less than the price of the equivalent medicine from another supplier to the NHS which had long been regulated, and appeared to be acceptable to, the Department of Health.”

“Phenytoin sodium capsules are already less expensive than the alternative equivalent drugs in the U.K. market,” a Flynn spokesman said, according to Bloomberg. “It beggars belief that the CMA seeks to punish Flynn for selling phenytoin capsules at a significant discount to phenytoin tablets.”

Pfizer and Flynn asked for the decision to be annulled and for the fines to be reduced or set aside. Pfizer also wrote that it wants the regulatory agency to pay its cost for the appeal.

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Flynn Pharma, Pfizer Inc.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS